We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+20.34%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.16B
AUM Growth
+$284M
Cap. Flow
+$60M
Cap. Flow %
1.44%
Top 10 Hldgs %
34.47%
Holding
129
New
1
Increased
41
Reduced
24
Closed
9

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$29.3M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$25M
3
BAX icon
Baxter International
BAX
+$21.2M
4
BPMC
Blueprint Medicines
BPMC
+$16.9M
5
IRON icon
Disc Medicine
IRON
+$16.9M

Top Sells

Rank Stock Value
1
CVET
Covetrus, Inc. Common Stock
CVET
+$35.1M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$16.4M
3
ARVN icon
Arvinas
ARVN
+$12.5M
4
GOSS icon
Gossamer Bio
GOSS
+$9.97M
5
OHPAU
Orion Acquisition Corp. Unit
OHPAU
+$9.87M

Sector Composition

Rank Sector Weight
1 Healthcare 97.77%
2 Consumer Staples 0.83%
3 Industrials 0.36%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
76
Biohaven
BHVN
$2.1B
$9.28M 0.22%
668,913
+497,641
+291% +$7.03M
NVCR icon
77
NovoCure
NVCR
$2.03B
$9.17M 0.22%
125,000
-50,000
-29% -$3.76M
MGNX icon
78
MacroGenics
MGNX
$259M
$7.54M 0.18%
1,123,096
-83,546
-7% -$458K
IRON icon
79
Disc Medicine
IRON
$3.06B
$6.75M 0.16%
+339,497
New +$16.9M
ICVX
80
DELISTED
Icosavax, Inc. Common Stock
ICVX
$6.2M 0.15%
781,000
– –
BMEA icon
81
Biomea Fusion
BMEA
$94.2M
$6.16M 0.15%
730,846
– –
VIGL
82
DELISTED
Vigil Neuroscience
VIGL
$5.9M 0.14%
471,958
– –
NVTA
83
DELISTED
Invitae Corporation
NVTA
$5.76M 0.14%
3,097,525
-289,330
-9% -$706K
LUNG icon
84
Pulmonx
LUNG
$101M
$5.5M 0.13%
652,400
+55,000
+9% +$523K
NVAX icon
85
Novavax
NVAX
$1.32B
$5.48M 0.13%
532,600
-66,700
-11% -$1.18M
GH icon
86
Guardant Health
GH
$22.3B
$5.44M 0.13%
200,000
– –
GMDA
87
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$5.31M 0.13%
4,119,883
– –
FSTX
88
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$4.75M 0.11%
751,889
– –
DSGN icon
89
Design Therapeutics
DSGN
$897M
$4.72M 0.11%
460,391
– –
MREO
90
Mereo BioPharma
MREO
$53.9M
$4.68M 0.11%
6,244,897
– –
KNTE
91
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$4.56M 0.11%
746,973
– –
BEAM icon
92
Beam Therapeutics
BEAM
$2.78B
$4.36M 0.1%
111,430
– –
ADAP
93
DELISTED
Adaptimmune Therapeutics
ADAP
$3.91M 0.09%
2,676,536
+318,992
+14% +$517K
ALT icon
94
Altimmune
ALT
$595M
$3.67M 0.09%
223,255
– –
XLO icon
95
Xilio Therapeutics
XLO
$60.4M
$3.67M 0.09%
97,348
– –
PRTK
96
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$3.24M 0.08%
1,734,037
– –
INZY
97
DELISTED
Inozyme Pharma
INZY
$3.24M 0.08%
3,086,027
+278,409
+10% +$487K
FULC icon
98
Fulcrum Therapeutics
FULC
$286M
$2.8M 0.07%
384,590
– –
OKUR
99
OnKure Therapeutics
OKUR
$160M
$2.66M 0.06%
114,319
– –
NKTX icon
100
Nkarta
NKTX
$167M
$2.36M 0.06%
393,389
-222,888
-36% -$2.25M
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Rock Springs Capital Management held 129 positions worth $4.16B, up 7.3% from $3.87B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management's Q4 2022 filing shows 1 new, 41 increased, 24 reduced and 9 closed positions. Its largest new stake was Disc Medicine: 339,497 shares worth $6.75M. The largest sale was Covetrus, Inc. Common Stock, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q4 2022 buy was Disc Medicine: 339,497 shares worth $6.75M.
  • Rock Springs Capital Management added most to Amylyx Pharmaceuticals in Q4 2022, an estimated $29.3M increase.
  • Rock Springs Capital Management's biggest Q4 2022 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $16.4M.
  • Rock Springs Capital Management fully exited Covetrus, Inc. Common Stock in Q4 2022, selling an estimated $35.1M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $4.16B portfolio in Q4 2022.
  • Rock Springs Capital Management opened 1 new position and closed 9 in Q4 2022.
  • Rock Springs Capital Management's portfolio value rose 7.3% quarter-over-quarter to $4.16B.

Based on Rock Springs Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.